AbbVie (ABBV)
(Delayed Data from NYSE)
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta
by Zacks Equity Research
The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.
Profit From Share Buyback Boom With These ETFs
by Sweta Killa
2018 is expected to be the second-busiest year for buybacks since the bull market began in 2009 buoyed by the new tax law.
Gilead Announces Positive Data on New HIV Therapy Biktarvy
by Zacks Equity Research
Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio
by Zacks Equity Research
Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP
by Zacks Equity Research
CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.
AbbVie (ABBV) Up 9.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbvie's Uterine Fibrosis Candidate Meets Goal in Study
by Zacks Equity Research
AbbVie's (ABBV) phase III study of its late stage candidate elagolix meets its primary endpoint in women with uterine fibroids.
Novartis Psoriasis Drug Cosentyx Positive in SCALP Study
by Zacks Equity Research
Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan
by Zacks Equity Research
AbbVie (ABBV) announces a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board.
Lilly's Taltz Positive in Phase III Label Expansion Study
by Zacks Equity Research
Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis.
Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning
by Zacks Equity Research
Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning
5 Solid Dividend Growth Stocks Amid Rising Rates
by Sweta Killa
Dividend growth stocks pose strong fundamentals and are lucrative, especially given the new tax legislation in the United States, rising yields and heightened volatility.
Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis
by Zacks Equity Research
Novartis' (NVS) psoriasis drug, Cosentyx is already approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up
by Zacks Equity Research
Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.
Add These 7 GARP Stocks to Your Portfolio for Better Returns
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre
by Zacks Equity Research
Gilead (GILD) topped earnings and sales expectations in the fourth quarter but the guidance for 2018 was disappointing due to further weakness in the HCV franchise.
Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View
by Zacks Equity Research
Centene's (CNC) fourth-quarter earnings were hurt by higher selling, general & administrative expenses.
Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the fourth quarter. Eliquis records solid sales.
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft
by Zacks Equity Research
Amgen (AMGN) misses expectations for both earnings and sales and also issues a lower-than-expected sales guidance for 2018. Shares decline in after-hours trading.
AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018
by Zacks Equity Research
AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.
5 Top Earnings Growth Stocks to Buy in February
by Tirthankar Chakraborty
We have shortlisted 5 top-rated stocks that have striking earnings growth and positive estimate revisions.
Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?
by Zacks Equity Research
Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.
Will Gilead (GILD) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.